1-20 of 45 results for subject:Co-careldopa
Librarians' tools
- Search time
- 0.189 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Co-careldopa
- We searched for
- subject_t:Co-careldopa OR subject_t:Duodopa OR subject_t:Levodopa/carbidopa OR subject_ses:418369
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to address shortages of Co-careldopa medication.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to address shortages of Co-careldopa medication.
The Department has been in contact with suppliers of co-careldopa immediate release and modified release tablets. There is good supply availability in the market for United Kingdom patients.
To ask the Secretary of State for Health and Social Care, what estimate he can provide of the size of the stockpiles of co-careldopa that were available for prescription or purchase in the UK prior to 31 October 2019.
To ask the Secretary of State for Health and Social Care, what estimate he can provide of the size of the stockpiles of co-careldopa that were available for prescription or purchase in the UK prior to 31 October 2019.
Our priority is to ensure that patients continue to have access to medicines and medical products they need. We are working closely with industry, the National Health Service and others in the supply chain to ensure that precautions are in place to mitigate against future possible risks of medicine shortages, including those linked to COVID-19 and the end of the transition period.
As set out in a letter from the Department to industry of 3 August, we are implementing a multi-layered approach, that involves asking suppliers to get trader ready, reroute their supply chains away from any potential disruption and stockpiling to a target level of six weeks on United Kingdom soil where this is possible. The letter is available at the following link:
None of the medicines listed were in the Government’s Essential Medicines Buffer Stock on the dates in question. Neither is it our current intention to include any of those medicines in the COVID-19 supportive medicines stockpile.
With regard to stocks of medicines on UK soil owned and held by suppliers, commercially sensitive information has been shared with the Department to support our potential ‘no deal’ EU exit, end of Transition Period and COVID-19 contingency programmes. For this reason, we cannot share information received from suppliers, including on their UK stock levels, with third parties.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the size of the stockpiles of co-careldopa that are available for prescription or purchase in the UK as of 15 September 2020.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the size of the stockpiles of co-careldopa that are available for prescription or purchase in the UK as of 15 September 2020.
Our priority is to ensure that patients continue to have access to medicines and medical products they need. We are working closely with industry, the National Health Service and others in the supply chain to ensure that precautions are in place to mitigate against future possible risks of medicine shortages, including those linked to COVID-19 and the end of the transition period.
As set out in a letter from the Department to industry of 3 August, we are implementing a multi-layered approach, that involves asking suppliers to get trader ready, reroute their supply chains away from any potential disruption and stockpiling to a target level of six weeks on United Kingdom soil where this is possible. The letter is available at the following link:
None of the medicines listed were in the Government’s Essential Medicines Buffer Stock on the dates in question. Neither is it our current intention to include any of those medicines in the COVID-19 supportive medicines stockpile.
With regard to stocks of medicines on UK soil owned and held by suppliers, commercially sensitive information has been shared with the Department to support our potential ‘no deal’ EU exit, end of Transition Period and COVID-19 contingency programmes. For this reason, we cannot share information received from suppliers, including on their UK stock levels, with third parties.
To ask the Secretary of State for Health and Social Care, when the Government last made an assessment of the stockpiling of co-careldopa that will be required in preparation for (a) a second wave of covid-19 and (b) the end of the transition period; and if he will publish that...
To ask the Secretary of State for Health and Social Care, when the Government last made an assessment of the stockpiling of co-careldopa that will be required in preparation for (a) a second wave of covid-19 and (b) the end of the transition period; and if he will publish that...
Our priority is to ensure that patients continue to have access to medicines and medical products they need. We are working closely with industry, the National Health Service and others in the supply chain to ensure that precautions are in place to mitigate against future possible risks of medicine shortages, including those linked to COVID-19 and the end of the transition period.
As set out in a letter from the Department to industry of 3 August, we are implementing a multi-layered approach, that involves asking suppliers to get trader ready, reroute their supply chains away from any potential disruption and stockpiling to a target level of six weeks on United Kingdom soil where this is possible. The letter is available at the following link:
None of the medicines listed were in the Government’s Essential Medicines Buffer Stock on the dates in question. Neither is it our current intention to include any of those medicines in the COVID-19 supportive medicines stockpile.
With regard to stocks of medicines on UK soil owned and held by suppliers, commercially sensitive information has been shared with the Department to support our potential ‘no deal’ EU exit, end of Transition Period and COVID-19 contingency programmes. For this reason, we cannot share information received from suppliers, including on their UK stock levels, with third parties.
I beg to move,
That this House has considered access to Duodopa.
It is a pleasure to serve under your chairmanship, Sir Edward. I thank the Minister for sparing the time to respond to this limited debate this afternoon. The subject is a serious one, especially for those people who contend with...
I beg to move,
That this House has considered access to Duodopa.
It is a pleasure to serve under your chairmanship, Sir Edward. I thank the Minister for sparing the time to respond to this limited debate this afternoon. The subject is a serious one, especially for those people who contend with...
I thank the hon. Gentleman for bringing this matter to Westminster Hall for consideration. I hope that the Minister will be able to respond positively. As a result of the background information that I got in relation to this issue, I would like to ask this question: does he agree...
I thank the hon. Gentleman for bringing this matter to Westminster Hall for consideration. I hope that the Minister will be able to respond positively. As a result of the background information that I got in relation to this issue, I would like to ask this question: does he agree...
I thank the hon. Gentleman for that intervention. I will come to that point later and respond to it.
That incorrectly assumes that the populations given the treatments are the same, which is not the case, as UK clinicians recommend Duodopa only if their patient cannot have deep brain stimulation or...
I thank the hon. Gentleman for that intervention. I will come to that point later and respond to it.
That incorrectly assumes that the populations given the treatments are the same, which is not the case, as UK clinicians recommend Duodopa only if their patient cannot have deep brain stimulation or...
I have been involved for 15 or 20 years in supporting Parkinson’s disease patients or those living with Parkinson’s disease, and I think it is terrific that Members of Parliament initiate debates that raise its profile, raise awareness and ask the Minister to come before us and share views on...
I have been involved for 15 or 20 years in supporting Parkinson’s disease patients or those living with Parkinson’s disease, and I think it is terrific that Members of Parliament initiate debates that raise its profile, raise awareness and ask the Minister to come before us and share views on...
I thank the hon. Gentleman very much for his kind words and support.
This issue is of great importance to a relatively small number of people, but given that the treatment is currently available through NHS England, to withdraw it on the basis of an apparently flawed assessment would cause concern...
I thank the hon. Gentleman very much for his kind words and support.
This issue is of great importance to a relatively small number of people, but given that the treatment is currently available through NHS England, to withdraw it on the basis of an apparently flawed assessment would cause concern...
It is a pleasure to serve under your chairmanship this afternoon, Sir Edward. I add my congratulations to those of my hon. Friend the Member for Montgomeryshire (Glyn Davies) to the hon. Member for Ealing, Southall (Mr Sharma) on securing the debate. It is right that we use the opportunity...
It is a pleasure to serve under your chairmanship this afternoon, Sir Edward. I add my congratulations to those of my hon. Friend the Member for Montgomeryshire (Glyn Davies) to the hon. Member for Ealing, Southall (Mr Sharma) on securing the debate. It is right that we use the opportunity...
I intervene only to reinforce the Minister’s point. I remember being involved in campaigning against NICE and calling it out for everything I could when bowel cancer drugs were not available. That was driven by my personal interest, but in time I have come to realise—partly because my son who...
I intervene only to reinforce the Minister’s point. I remember being involved in campaigning against NICE and calling it out for everything I could when bowel cancer drugs were not available. That was driven by my personal interest, but in time I have come to realise—partly because my son who...
I can only concur that many of us benefit from lectures from our children, and it is nice to know that my hon. Friend does. I agree with the point made by the hon. Member for Ealing, Southall. If NICE has made a mistake, if something has been wrong in...
I can only concur that many of us benefit from lectures from our children, and it is nice to know that my hon. Friend does. I agree with the point made by the hon. Member for Ealing, Southall. If NICE has made a mistake, if something has been wrong in...
Motion that this House has considered access to Duodopa. Agreed to on question.
Motion that this House has considered access to Duodopa. Agreed to on question.
To ask the Secretary of State for Health, how many patients have received levodopa-carbidopa intestinal gel under NHS England's clinical commissioning policy since July 2015.
To ask the Secretary of State for Health, how many patients have received levodopa-carbidopa intestinal gel under NHS England's clinical commissioning policy since July 2015.
75 patients have accessed levodopa-carbidopa intestinal gel under NHS England's clinical commissioning policy since July 2015.
To ask the Secretary of State for Health, what steps he is taking to introduce the drug Duodopa for the treatment of NHS patients with Parkinson's disease.
To ask the Secretary of State for Health, what steps he is taking to introduce the drug Duodopa for the treatment of NHS patients with Parkinson's disease.
On 2 July 2015, NHS England announced that Duodopa will now be routinely commissioned by NHS England for patients meeting the inclusion criteria agreed by the Neurosciences Clinical Reference Group.
The specific commissioning policy on Duodopa is available here:
http://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-d/d04/
This decision followed a three-month public consultation on the principles and processes NHS England will follow when making investment decisions.
To ask the Secretary of State for Health, what recent discussions he has had with clinical and medical bodies on potential links between use of levodopa and gambling problems.
To ask the Secretary of State for Health, what recent discussions he has had with clinical and medical bodies on potential links between use of levodopa and gambling problems.
There have not been any recent discussions with clinical and medical bodies regarding the potential link between the use of levodopa and gambling problems. Gambling problems are recognised to be a risk associated with levodopa and dopamine agonists used to treat Parkinson’s disease.
There have been warnings about impulse disorders, including pathological gambling, in the product information for all medicines containing levodopa since 2006 and these warnings are also reflected in the British National Formulary provided to all prescribers within the National Health Service.
The risk of abnormal behaviours including pathological gambling is also highlighted in the 2006 NICE Clinical Guideline 35, Parkinson’s Disease: Diagnosis and management in primary and secondary care.
To ask the Secretary of State for Health, what progress NHS England has made in its review of the draft clinical commissioning policy for Duodopa; and how the views of clinicians and those affected by Parkinson's disease have been taken into account during that review.
To ask the Secretary of State for Health, what progress NHS England has made in its review of the draft clinical commissioning policy for Duodopa; and how the views of clinicians and those affected by Parkinson's disease have been taken into account during that review.
On 24 March 2015, NHS England launched a 30 day public consultation on a proposed number of new products for specialised services, including a clinical commissioning policy for co-careldopa intestinal gel (Duodopa).
There has already been extensive engagement on these national specifications and policies, as they have been developed with the support and input of lead clinicians and patient and public representatives. This approach has helped ensure that the views of key stakeholders have informed and influenced the development of the policies and specifications so far.
The consultation was open to anyone who wished to respond. Further information about the consultation, together with a copy of the draft policy, can be found on NHS England’s website and accessed via the following link:
https://www.engage.england.nhs.uk/consultation/specialised-services-consultation
To ask the Secretary of State for Health, how many submissions NHS England has received on the consultation on Duodopa levodopa-carbidopa intestinal gel clinical commissioning policy.
To ask the Secretary of State for Health, how many submissions NHS England has received on the consultation on Duodopa levodopa-carbidopa intestinal gel clinical commissioning policy.
NHS England has advised that there were 35 online responses received during the 30 day consultation period.
To ask the Secretary of State for Health, when he expects NHS England to take a decision on the draft clinical commissioning policy for Duodopa.
To ask the Secretary of State for Health, when he expects NHS England to take a decision on the draft clinical commissioning policy for Duodopa.
NHS England has advised that a decision on the draft clinical commissioning policy for Duodopa is expected by the end of June.
NHS England has further advised that there will be a formal announcement of all the decisions relating to the clinical commissioning policies which have recently been consulted on at the end of June.
To ask the Secretary of State for Health, how NHS England will communicate the decision on the draft clinical commissioning policy for Duodopa to (a) clinicians and (b) patients.
To ask the Secretary of State for Health, how NHS England will communicate the decision on the draft clinical commissioning policy for Duodopa to (a) clinicians and (b) patients.
NHS England has advised that a decision on the draft clinical commissioning policy for Duodopa is expected by the end of June.
NHS England has further advised that there will be a formal announcement of all the decisions relating to the clinical commissioning policies which have recently been consulted on at the end of June.